NovaBridge Biosciences (NBP) Accumulated Depreciation (2020 - 2021)
NovaBridge Biosciences (NBP) posted quarterly Accumulated Depreciation of -$5.7 billion for Q2 2021, down 23.3% on a QoQ basis from -$4.7 billion in Q4 2020.
NovaBridge Biosciences (NBP) Accumulated Depreciation (2020 - 2021) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Accumulated Depreciation for 2 consecutive years, with -$5.7 billion the latest figure, recorded in Q2 2021.
- Quarterly Accumulated Depreciation changed N/A year-over-year to -$5.7 billion in Q2 2021, while the trailing twelve-month figure through Jun 2021 was -$5.7 billion (changed N/A YoY) and the FY2020 annual result came in at -$4.7 billion, changed N/A from the prior year.
- Accumulated Depreciation fell to -$5.7 billion in Q2 2021 per NBP's latest filing, from -$4.7 billion in the prior quarter.
- Over the last five years, Accumulated Depreciation for NBP reached as high as -$4.7 billion in Q4 2020 and fell as low as -$5.7 billion in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -5.75 Bn |
| Dec 31, 2020 | -4.66 Bn |